Nanjing Pharmaceutical Group Company Limited (SHA:600713)
5.24
+0.06 (1.16%)
Sep 14, 2026, 3:00 PM CST
SHA:600713 Revenue
Nanjing Pharmaceutical Group Company had revenue of 13.98B CNY in the quarter ending June 30, 2026, with 1.88% growth. This brings the company's revenue in the last twelve months to 54.82B, up 0.71% year-over-year. In the year 2025, Nanjing Pharmaceutical Group Company had annual revenue of 54.96B with 2.36% growth.
Revenue (ttm)
54.82B
Revenue Growth
+0.71%
P/S Ratio
0.12
Revenue / Employee
11.67M
Employees
4,697
Market Cap
6.78B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.96B | 1.27B | 2.36% |
| Dec 31, 2024 | 53.70B | 106.51M | 0.20% |
| Dec 31, 2023 | 53.59B | 3.37B | 6.71% |
| Dec 31, 2022 | 50.22B | 5.10B | 11.30% |
| Dec 31, 2021 | 45.12B | 5.31B | 13.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Int'l Group | 34.20B |
| Yifan Pharmaceutical | 4.97B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 3.21B |
| GuangYuYuan Chinese Herbal Medicine | 1.41B |
| Zhejiang Wolwo Bio-Pharmaceutical | 1.09B |
| Hangzhou Minsheng Healthcare | 854.51M |
| Chongqing Lummy Pharmaceutical | 748.94M |
| Hangzhou Bio-Sincerity Pharma-Tech | 709.72M |